Anti-ATL effect of OR21 and EPZ in a TL-Om1 xenograft mouse model. (A) Experimental protocol for the establishment of the TL-Om1 xenograft mouse model and treatment with OR21 and/or EPZ. NOG mice inoculated with TL-Om1 cells subcutaneously were treated with vehicle (1% dimethyl sulfoxide, intraperitoneally, twice per week and 0.5% CMC-Na + 0.1% Tween-80 solution, oral gavage, daily, n = 8), OR21 (3.39 mg/kg, intraperitoneally, twice a week, n = 8), EPZ (100 mg/kg, oral gavage, daily, n = 8), or OR21 + EPZ (3.39 mg/kg OR21 and 100 mg/kg EPZ, n = 7) as indicated by the red and green arrowheads. (B-C) Mean tumor volume (B) and weight (C) in mice. Differences between vehicle and each treatment group were tested using Dunnett test. (D) Concentration of hemoglobin (HGB) and complete blood counts, including white blood cells (WBC) and platelets (PLT), from mice sacrificed at 21 days after the first treatment. Differences between each group were tested using Tukey test. ∗P < .05, ∗∗P < .01. n.s., not significant.